Securities Registration (section 12(b)) (8-a12b)
2023年3月14日 - 5:38AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
AstraZeneca
PLC
(Exact name of registrant as specified in its charter)
England and Wales
(State or other jurisdiction of incorporation or
organization) |
Not Applicable
(I.R.S. Employer
Identification No.) |
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, United Kingdom
(Address of principal executive offices) |
CB2 0AA
(Zip Code) |
AstraZeneca Finance
LLC
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or
organization) |
86-3730535
(I.R.S. Employer
Identification No.) |
|
|
1209 Orange Street
Wilmington, Delaware
United
States of America
(Address of principal executive offices) |
19801
(Zip Code) |
Securities to be registered pursuant to Section 12(b) of
the Act:
Title
of each class
to be so registered |
|
Name
of each exchange on which
each class is to be registered |
4.875%
Notes due 2028 (and the guarantee of AstraZeneca PLC related thereto) |
|
The
Nasdaq Stock Market LLC |
4.900%
Notes due 2030 (and the guarantee of AstraZeneca PLC related thereto) |
|
The
Nasdaq Stock Market LLC |
4.875%
Notes due 2033 (and the guarantee of AstraZeneca PLC related thereto) |
|
The
Nasdaq Stock Market LLC |
If
this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective
pursuant to General Instruction A.(c) or (e), check the following box. x
If
this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective
pursuant to General Instruction A.(d) or (e), check the following box. ¨
If
this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨
Securities Act registration statement or Regulation
A offering statement file number to which this form relates: Not applicable.
Securities to be registered pursuant to Section 12(g) of
the Act: None.
INFORMATION REQUIRED IN REGISTRATION STATEMENT
AstraZeneca PLC (“AstraZeneca”)
and AstraZeneca Finance LLC (“AstraZeneca Finance” and, together with AstraZeneca, the “Registrants”) filed with
the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act of 1933,
as amended (the “Securities Act”), a prospectus supplement, dated February 28, 2023 (the “Prospectus Supplement”),
and the accompanying prospectus, dated May 24, 2021 (the “Prospectus”). The Prospectus Supplement relates to the offering
of $1,100,000,000 4.875% Notes due 2028, $650,000,000 4.900% Notes due 2030 and $500,000,000 4.875% Notes due 2033 issued by AstraZeneca
Finance and fully and unconditionally guaranteed by AstraZeneca. The Prospectus forms a part of the Registrants’ Registration Statement
on Form F-3 (File No. 333-256406) filed with the Commission on May 24, 2021. The Prospectus Supplement and the Prospectus
are incorporated herein by reference to the extent set forth below.
Item 1. Description of Registrant’s Securities to Be Registered.
Reference is made to the information
set forth under the headings “Description of Debt Securities and Guarantees” on pages 14 through 30 and “Certain
UK and U.S. Federal Tax Considerations” on pages 35 through 43 of the Prospectus; and to the information set forth under the
headings “Description of Notes” on pages S-12 through S-17 and “Taxation” on page S-18 of the Prospectus
Supplement, which information is incorporated herein by reference.
Item 2. Exhibits.
Exhibit
No. |
Description |
1.1 |
Registration
Statement on Form F-3, including the Prospectus (incorporated herein by reference to the Registration Statement on Form F-3
filed with the Commission by AstraZeneca PLC and AstraZeneca Finance LLC on May 24, 2021 (File No. 333-256406)). |
1.2 |
Prospectus
Supplement (incorporated herein by reference to the prospectus filed with the Commission by AstraZeneca PLC and AstraZeneca Finance
LLC on March 2, 2023 pursuant to Rule 424(b2)). |
4.1 |
Indenture,
dated as of May 28, 2021, among AstraZeneca Finance LLC, as issuer, AstraZeneca PLC, as guarantor, and The Bank of New York,
as trustee (incorporated by reference to Exhibit 4.2 to the foreign private issuer report on Form 6-K filed with the Commission
by AstraZeneca PLC on May 28, 2021). |
4.2 |
Officers’
Certificate pursuant to Section 2.08 of the Indenture setting forth the terms of the AstraZeneca Finance securities, including
forms of the global notes for the 4.875% Notes due 2028, the 4.900% Notes due 2030 and the 4.875% Notes due 2033 (incorporated by
reference to Exhibit 4.1 to the foreign private issuer report on Form 6-K filed with the Commission by AstraZeneca PLC
on March 3, 2023). |
SIGNATURE
Pursuant to the requirements
of Section 12 of the Securities Exchange Act of 1934, each Registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereto duly authorized.
Dated: March 13,
2023 |
AstraZeneca
PLC |
|
(Registrant) |
|
|
|
By: |
/s/
Jonathan Slade |
|
|
Name: |
Jonathan
Slade |
|
|
Title: |
Group Treasurer |
|
AstraZeneca
Finance LLC |
|
(Registrant) |
|
|
|
By: |
/s/
David E. White |
|
|
Name: |
David E.
White |
|
|
Title: |
President, Treasurer
and Director |
AstraZeneca (NYSE:AZN)
過去 株価チャート
から 12 2024 まで 1 2025
AstraZeneca (NYSE:AZN)
過去 株価チャート
から 1 2024 まで 1 2025